Literature DB >> 12529963

Overexpression of the neutral amino acid transporter ASCT2 in human colorectal adenocarcinoma.

Deborah Witte1, Najeeba Ali, Nicole Carlson, Mamoun Younes.   

Abstract

Cancer cells have increased amino acid transport and retention. Our aim was to determine whether the neutral amino acid transporter ASCT2 is expressed in colorectal adenocarcinomas (CRC), and whether its expression is of biological significance. Western blot analysis was performed on 4 cases of CRC. Immunohistochemical staining was performed on sections of 63 CRC, and the percent of positive cells was determined. Survival analysis was performed using the Kaplan-Meier method. Western blot analysis showed a 50 kDa protein, corresponding to ASCT2, in 3 of the 4 CRC samples. Immunohistostaining showed lack of ASCT2 immunoreactivity in 41% of the cases. ASCT2 immunoreactivity was present in 1-25% of the cancer cells in 24% of the cases, 26-50% of the cells in 13%, and in > 50% of the cells in 22% of the cases. Patient survival decreased with increased percentage of ASCT2-positive cancer cells (p = 0.0002). These results indicate that ASCT2 is expressed in a significant number of CRC, and that ASCT2 expression is associated with aggressive biological behavior. Larger studies with multivariate analysis are needed to determine whether ASCT2 expression is an independent prognostic marker in CRC.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12529963

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  28 in total

1.  Clinical significance of coexpression of L-type amino acid transporter 1 (LAT1) and ASC amino acid transporter 2 (ASCT2) in lung adenocarcinoma.

Authors:  Tomohiro Yazawa; Kimihiro Shimizu; Kyoichi Kaira; Toshiteru Nagashima; Yoichi Ohtaki; Jun Atsumi; Kai Obayashi; Shushi Nagamori; Yoshikatsu Kanai; Tetsunari Oyama; Izumi Takeyoshi
Journal:  Am J Transl Res       Date:  2015-06-15       Impact factor: 4.060

2.  Prognostic significance of L-type amino acid transporter 1 (LAT1) expression in patients with ovarian tumors.

Authors:  Kyoichi Kaira; Kazuto Nakamura; Takashi Hirakawa; Hisao Imai; Hideyuki Tominaga; Noboru Oriuchi; Shushi Nagamori; Yoshikatsu Kanai; Norifumi Tsukamoto; Tetsunari Oyama; Takayuki Asao; Takashi Minegishi
Journal:  Am J Transl Res       Date:  2015-06-15       Impact factor: 4.060

3.  An anti-ASCT2 monoclonal antibody suppresses gastric cancer growth by inducing oxidative stress and antibody dependent cellular toxicity in preclinical models.

Authors:  Aya Osanai-Sasakawa; Kenta Hosomi; Yoshiki Sumitomo; Takuya Takizawa; Shiho Tomura-Suruki; Minami Imaizumi; Noriyuki Kasai; Tze Wei Poh; Kazuya Yamano; Wei Peng Yong; Koji Kono; Satoshi Nakamura; Toshihiko Ishii; Ryuichiro Nakai
Journal:  Am J Cancer Res       Date:  2018-08-01       Impact factor: 6.166

4.  2-Amino-4-bis(aryloxybenzyl)aminobutanoic acids: A novel scaffold for inhibition of ASCT2-mediated glutamine transport.

Authors:  Michael L Schulte; Alexandra B Khodadadi; Madison L Cuthbertson; Jarrod A Smith; H Charles Manning
Journal:  Bioorg Med Chem Lett       Date:  2015-12-11       Impact factor: 2.823

5.  Anti-tumor efficacy evaluation of a novel monoclonal antibody targeting neutral amino acid transporter ASCT2 using patient-derived xenograft mouse models of gastric cancer.

Authors:  Noriyuki Kasai; Aya Sasakawa; Kenta Hosomi; Tze Wei Poh; Bernadette Lynn Chua; Wei Peng Yong; Jimmy So; Shing Leng Chan; Richie Soong; Koji Kono; Toshihiko Ishii; Kazuya Yamano
Journal:  Am J Transl Res       Date:  2017-07-15       Impact factor: 4.060

Review 6.  The Na+/Cl--Coupled, Broad-Specific, Amino Acid Transporter SLC6A14 (ATB0,+): Emerging Roles in Multiple Diseases and Therapeutic Potential for Treatment and Diagnosis.

Authors:  Mohd Omar F Sikder; Shengping Yang; Vadivel Ganapathy; Yangzom D Bhutia
Journal:  AAPS J       Date:  2017-12-04       Impact factor: 4.009

7.  Regulation of glutamine carrier proteins by RNF5 determines breast cancer response to ER stress-inducing chemotherapies.

Authors:  Young Joo Jeon; Sihem Khelifa; Boris Ratnikov; David A Scott; Yongmei Feng; Fabio Parisi; Chelsea Ruller; Eric Lau; Hyungsoo Kim; Laurence M Brill; Tingting Jiang; David L Rimm; Robert D Cardiff; Gordon B Mills; Jeffrey W Smith; Andrei L Osterman; Yuval Kluger; Ze'ev A Ronai
Journal:  Cancer Cell       Date:  2015-03-09       Impact factor: 31.743

8.  A metabolic perturbation by U0126 identifies a role for glutamine in resveratrol-induced cell death.

Authors:  Michael R Freeman; Jayoung Kim; Michael P Lisanti; Dolores Di Vizio
Journal:  Cancer Biol Ther       Date:  2011-12-01       Impact factor: 4.742

Review 9.  Novel therapeutic targets of tumor metabolism.

Authors:  Rigel J Kishton; Jeffrey C Rathmell
Journal:  Cancer J       Date:  2015 Mar-Apr       Impact factor: 3.360

10.  SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival.

Authors:  Mohamed Hassanein; Megan D Hoeksema; Masakazu Shiota; Jun Qian; Bradford K Harris; Heidi Chen; Jonathan E Clark; William E Alborn; Rosana Eisenberg; Pierre P Massion
Journal:  Clin Cancer Res       Date:  2012-12-04       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.